Search Results

Site Search

Top 5 Mayo Clinic Laboratories advancements in 2024 - Insights

Five of the most significant advancements from Mayo Clinic Laboratories in 2024 to enhance diagnostics and patient care globally.

Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights

Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. - Insights

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...

Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S. - Insights

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...

MAG Antibody Testing [Test in Focus] - Insights

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat...

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. - Insights

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S. - Insights

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...

Testing aids nicotine-use cessation: Paul Jannetto, Ph.D. - Insights

Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients...

Test for LDL subtype helps manage coronary risk: Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D. - Insights

Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...